Baseline demographics and disease characteristics
| Group 3 cemiplimab 350 mg intravenously Q3W (n=56) | Group 1 cemiplimab 3 mg/kg intravenously Q2W (n=59) | Total (Groups 1+3) (n=115) | |
| Median age, years (range) | 71 (38 to 90) | 71 (38 to 93) | 71 (38 to 93) |
| <65, n (%) | 14 (25.0) | 16 (27.1) | 30 (26.1) |
| ≥65 to <75, n (%) | 20 (35.7) | 23 (39.0) | 43 (37.4) |
| ≥75, n (%) | 22 (39.3) | 20 (33.9) | 42 (36.5) |
| Male, n (%) | 48 (85.7) | 54 (91.5) | 102 (88.7) |
| ECOG PS, n (%) | |||
| 0 | 25 (44.6) | 23 (39.0) | 48 (41.7) |
| 1 | 31 (55.4) | 36 (61.0) | 67 (58.3) |
| Primary CSCC site: head and neck, n (%) | 31 (55.4) | 38 (64.4) | 69 (60.0) |
| Metastatic status, n (%) | |||
| Distant | 43 (76.8) | 45 (76.3) | 88 (76.5) |
| Nodal | 12 (21.4) | 14 (23.7) | 26 (22.6) |
| Missing | 1 (1.8) | 0 (0.0) | 1 (0.9) |
| Prior cancer-related systemic therapy, n (%) | 20 (35.7) | 33 (55.9) | 53 (46.1) |
| Prior cancer-related radiotherapy, n (%) | 38 (67.9) | 50 (84.7) | 88 (76.5) |
CSCC, cutaneous squamous cell carcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; Q2W, every 2 weeks; Q3W, every 3 weeks.